Leucine

Leucine develops software for pharmaceutical manufacturers that replaces paper-based batch records and quality documentation with digital, compliance-oriented workflows. Its platform spans three product lines: a manufacturing execution system (batch execution, batch intelligence, production logbooks, expedited batch release, shop-floor monitoring and work-in-progress inventory tracking), a quality management system (market complaint triage, AI-assisted investigations, FDA 483 and warning-letter analysis, and cleaning validation), and a laboratory execution system (environmental monitoring and digital instrument logbooks). Products include AI Investigator, which produces root cause analysis and CAPA recommendations, and FDA Tracker, which analyses FDA 483 trends and warning letters.

The company originally marketed a "Compliance Cloud" platform described as a digital twin of the pharma manufacturing shop floor, providing real-time performance monitoring, compliance management, deviation root cause analysis, and automatically generated manufacturing records and audit reports. In October 2023 it announced the beta of Leucine10x, an LLM-based framework of AI co-pilots that digitizes paper SOPs, builds dynamic production plans and accelerates deviation investigations using text records, logs and staff interview transcripts. Leucine states it embeds 21 CFR Part 11, EU Annex 11 and GMP requirements into workflows, signatures and audit trails, and that its architecture supports multi-site, multi-country deployments with regional regulatory frameworks.

Founding story

Leucine was founded in 2019 by Vivek Gera and Mustaq Singh Bijral. Gera, previously a compliance and automation consultant to Fortune 500 companies and formerly at Rio Tinto, observed the scale and cost of non-compliance in pharmaceutical manufacturing and found that legacy vendors offered neither compliance by design nor insights from the data they held. He teamed with Bijral, whose background is in product management and data science, to build a data-driven platform with built-in compliance guidelines and process interlocks.

Business model

Business-to-business enterprise software sold to pharmaceutical manufacturers, deployed across customers' manufacturing facilities and sites.

SaaS subscriptions with tiered pricing that scales with volume. As of October 2023 the average contract value was about $100,000, which the CEO said was moving toward $300,000-$400,000, with revenue split roughly 50/50 between the US and India.

Traction

At the time of the 2023 Series A the platform was deployed at more than 30 companies across over 300 manufacturing facilities in 10 countries, with a doubling of facilities and a 300% increase in users over the prior 12 months. The company's website later cited more than 400 GMP facilities, support for 10+ regulatory frameworks and a 100% go-live success rate, and reports over $10 million raised in total funding.

Latest developments

The company markets an integrated AI-powered platform across manufacturing, quality and laboratory operations, including 10x MES, 10x QMS and 10x LES, AI Investigator for root cause analysis and CAPA, and an FDA Tracker for 483 and warning-letter analysis. It has published a white paper on navigating FDA observations in 2025 and is scheduled to appear at industry events through 2026; its CPO has issued a letter to customers outlining an AI roadmap.